Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.70 |
| ▸ | HTR2C | P28335 | 9/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166210 | 1.00 | HTR2A (0.70) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL3166540 | 0.86 | HTR2A (0.72) | HTR2AHTR2CKCNH2NFE2L2CYP2D6 | |
| SCHEMBL3166547 | 0.86 | HTR2A (0.72) | HTR2AHTR2CKCNH2NFE2L2CYP2D6 | |
| SCHEMBL3157074 | 0.85 | HTR2A (0.70) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL3157079 | 0.85 | HTR2A (0.70) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL3171403 | 0.83 | HTR2A (1.00) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL3171411 | 0.83 | HTR2A (1.00) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL16495124 | 0.83 | HTR2A (0.49) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3161664 | 0.82 | HTR2A (0.66) | HTR2AHTR2CKCNH2NFE2L2PTGS1 | |
| SCHEMBL3161674 | 0.82 | HTR2A (0.66) | HTR2AHTR2CKCNH2NFE2L2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 552/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 552/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.